KOPIN CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that KOPIN CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $1.53M | Apr 13, 2026 |
| FY2025 | Dec 28, 2024 | $1.01M | Apr 13, 2026 |
| FY2024 | Dec 30, 2023 | $1.89M | Apr 17, 2025 |
| FY2024 | Dec 31, 2022 | $1.67M | Apr 17, 2025 |
| FY2023 | Dec 25, 2021 | $4.42M | Mar 14, 2024 |
| FY2020 | Dec 26, 2020 | $13.92M | Mar 5, 2021 |
| FY2020 | Sep 26, 2020 | $9.51M | Mar 5, 2021 |
| FY2020 | Jun 27, 2020 | $8.82M | Mar 5, 2021 |
| FY2020 | Mar 28, 2020 | $7.88M | Mar 5, 2021 |
| FY2020 | Dec 28, 2019 | $8.73M | Mar 5, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $39.32M | Apr 13, 2026 |
| FY2025 | Dec 28, 2024 | $50.34M | Apr 13, 2026 |
| FY2024 | Dec 30, 2023 | $40.39M | Apr 17, 2025 |
| FY2024 | Dec 31, 2022 | $47.40M | Apr 17, 2025 |
| FY2023 | Dec 25, 2021 | $45.67M | Mar 14, 2024 |
| FY2022 | Dec 26, 2020 | $40.13M | Mar 14, 2023 |
| FY2021 | Dec 28, 2019 | $29.52M | Mar 14, 2022 |
| FY2020 | Dec 29, 2018 | $24.47M | Mar 5, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 26, 2020 | $3.30M | Mar 5, 2021 |
| FY2020 | Sep 26, 2020 | $1.66M | Mar 5, 2021 |
| FY2020 | Jun 27, 2020 | $1.89M | Mar 5, 2021 |
| FY2020 | Mar 28, 2020 | $271.0K | Mar 5, 2021 |
| FY2020 | Dec 28, 2019 | $1.19M | Mar 5, 2021 |
| FY2020 | Sep 28, 2019 | $265.0K | Mar 5, 2021 |
| FY2020 | Jun 29, 2019 | ($808.0K) | Mar 5, 2021 |
| FY2020 | Mar 30, 2019 | ($1.26M) | Mar 5, 2021 |
| FY2019 | Dec 29, 2018 | $1.44M | Mar 11, 2020 |
| FY2019 | Sep 29, 2018 | ($16.0K) | Mar 11, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $2.61M | Apr 13, 2026 |
| FY2025 | Dec 28, 2024 | ($43.88M) | Apr 13, 2026 |
| FY2024 | Dec 30, 2023 | ($19.75M) | Apr 17, 2025 |
| FY2024 | Dec 31, 2022 | ($19.33M) | Apr 17, 2025 |
| FY2023 | Dec 25, 2021 | ($13.43M) | Mar 14, 2024 |
| FY2020 | Dec 26, 2020 | $1.26M | Mar 5, 2021 |
| FY2020 | Sep 26, 2020 | ($957.0K) | Mar 5, 2021 |
| FY2020 | Jun 27, 2020 | ($1.12M) | Mar 5, 2021 |
| FY2020 | Mar 28, 2020 | ($3.60M) | Mar 5, 2021 |
| FY2020 | Dec 28, 2019 | ($7.29M) | Mar 5, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | ($9.85M) | Apr 13, 2026 |
| FY2025 | Dec 28, 2024 | ($43.11M) | Apr 13, 2026 |
| FY2024 | Dec 30, 2023 | ($17.18M) | Apr 17, 2025 |
| FY2024 | Dec 31, 2022 | ($21.79M) | Apr 17, 2025 |
| FY2023 | Dec 25, 2021 | ($13.78M) | Mar 14, 2024 |
| FY2022 | Dec 26, 2020 | ($4.76M) | Mar 14, 2023 |
| FY2021 | Dec 28, 2019 | ($26.38M) | Mar 14, 2022 |
| FY2020 | Dec 29, 2018 | ($39.97M) | Mar 5, 2021 |
| FY2019 | Dec 30, 2017 | ($30.30M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | ($20.47M) | Nov 7, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $6.69M | Apr 13, 2026 |
| FY2025 | Dec 28, 2024 | $5.83M | Apr 13, 2026 |
| FY2024 | Dec 30, 2023 | $3.60M | Apr 17, 2025 |
| FY2024 | Dec 31, 2022 | $8.39M | Apr 17, 2025 |
| FY2023 | Dec 25, 2021 | $6.31M | Mar 14, 2024 |
| FY2022 | Dec 26, 2020 | $3.92M | Mar 14, 2023 |
| FY2021 | Dec 28, 2019 | $9.13M | Mar 14, 2022 |
| FY2020 | Dec 29, 2018 | $12.55M | Mar 5, 2021 |
| FY2019 | Dec 30, 2017 | $15.52M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $15.25M | Nov 7, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $16.30M | Apr 13, 2026 |
| FY2025 | Dec 28, 2024 | $22.84M | Apr 13, 2026 |
| FY2024 | Dec 30, 2023 | $21.84M | Apr 17, 2025 |
| FY2024 | Dec 31, 2022 | $17.97M | Apr 17, 2025 |
| FY2023 | Dec 25, 2021 | $18.10M | Mar 14, 2024 |
| FY2022 | Dec 26, 2020 | $11.82M | Mar 14, 2023 |
| FY2021 | Dec 28, 2019 | $21.32M | Mar 14, 2022 |
| FY2020 | Dec 29, 2018 | $27.21M | Mar 5, 2021 |
| FY2019 | Dec 30, 2017 | $20.54M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $16.96M | Nov 7, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | ($15.54M) | Apr 13, 2026 |
| FY2025 | Dec 28, 2024 | ($14.23M) | Apr 13, 2026 |
| FY2024 | Dec 30, 2023 | ($15.26M) | Apr 17, 2025 |
| FY2024 | Dec 31, 2022 | ($17.69M) | Apr 17, 2025 |
| FY2023 | Dec 25, 2021 | ($10.75M) | Mar 14, 2024 |
| FY2022 | Dec 26, 2020 | ($4.42M) | Mar 14, 2023 |
| FY2021 | Dec 28, 2019 | ($21.03M) | Mar 14, 2022 |
| FY2020 | Dec 29, 2018 | ($28.10M) | Mar 5, 2021 |
| FY2019 | Dec 30, 2017 | ($25.91M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | ($26.17M) | Nov 7, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $1.44M | Apr 13, 2026 |
| FY2025 | Dec 28, 2024 | $815.3K | Apr 13, 2026 |
| FY2024 | Dec 30, 2023 | $949.5K | Apr 17, 2025 |
| FY2024 | Dec 31, 2022 | $832.7K | Apr 17, 2025 |
| FY2023 | Dec 25, 2021 | $1.03M | Mar 14, 2024 |
| FY2022 | Dec 26, 2020 | $542.9K | Mar 14, 2023 |
| FY2021 | Dec 28, 2019 | $170.2K | Mar 14, 2022 |
| FY2020 | Dec 29, 2018 | $1.18M | Mar 5, 2021 |
| FY2019 | Dec 30, 2017 | $2.79M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $394.9K | Nov 7, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $108.39M | Apr 13, 2026 |
| FY2025 | Dec 28, 2024 | $70.77M | Apr 13, 2026 |
| FY2024 | Dec 30, 2023 | $49.31M | Apr 17, 2025 |
| FY2023 | Dec 31, 2022 | $43.75M | Mar 14, 2024 |
| FY2022 | Dec 25, 2021 | $63.01M | Mar 14, 2023 |
| FY2021 | Dec 26, 2020 | $47.55M | Mar 14, 2022 |
| FY2020 | Dec 28, 2019 | $43.05M | Mar 5, 2021 |
| FY2019 | Dec 29, 2018 | $59.55M | Mar 11, 2020 |
| FY2018 | Dec 30, 2017 | $91.32M | Nov 7, 2019 |
| FY2017 | Dec 31, 2016 | $87.83M | Mar 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $36.72M | Apr 13, 2026 |
| FY2025 | Dec 28, 2024 | $47.48M | Apr 13, 2026 |
| FY2024 | Dec 30, 2023 | $19.80M | Apr 17, 2025 |
| FY2023 | Dec 31, 2022 | $19.76M | Mar 14, 2024 |
| FY2022 | Dec 25, 2021 | $23.38M | Mar 14, 2023 |
| FY2021 | Dec 26, 2020 | $19.25M | Mar 14, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $64.12M | Apr 13, 2026 |
| FY2025 | Dec 28, 2024 | $23.28M | Apr 13, 2026 |
| FY2024 | Dec 30, 2023 | $29.51M | Apr 17, 2025 |
| FY2023 | Dec 31, 2022 | $24.16M | Mar 14, 2024 |
| FY2022 | Dec 25, 2021 | $39.80M | Mar 14, 2023 |
| FY2021 | Dec 26, 2020 | $28.44M | Mar 14, 2022 |
| FY2020 | Dec 28, 2019 | $28.61M | Mar 5, 2021 |
| FY2019 | Dec 29, 2018 | $47.86M | Mar 11, 2020 |
| FY2018 | Dec 30, 2017 | $76.76M | Nov 7, 2019 |
| FY2017 | Dec 31, 2016 | $74.08M | Mar 23, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 25, 2021 | $0 | Mar 14, 2022 |
| FY2021 | Dec 26, 2020 | $0 | Mar 14, 2022 |
| FY2020 | Dec 28, 2019 | $0 | Mar 5, 2021 |
| FY2020 | Dec 29, 2018 | $331.3K | Mar 5, 2021 |
| FY2019 | Dec 30, 2017 | $1.78M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $844.0K | Nov 7, 2019 |
| FY2016 | Dec 26, 2015 | $946.1K | Mar 23, 2017 |
| FY2015 | Dec 27, 2014 | $976.5K | Mar 4, 2016 |
| FY2014 | Dec 28, 2013 | $1.02M | Mar 12, 2015 |
| FY2016 | Dec 29, 2012 | $976.5K | Mar 23, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | ($399.42M) | Apr 13, 2026 |
| FY2025 | Dec 28, 2024 | ($402.03M) | Apr 13, 2026 |
| FY2024 | Dec 30, 2023 | ($358.16M) | Apr 17, 2025 |
| FY2023 | Dec 31, 2022 | ($338.41M) | Mar 14, 2024 |
| FY2022 | Dec 25, 2021 | ($319.08M) | Mar 14, 2023 |
| FY2021 | Dec 26, 2020 | ($305.65M) | Mar 14, 2022 |
| FY2020 | Dec 28, 2019 | ($301.24M) | Mar 5, 2021 |
| FY2019 | Dec 29, 2018 | ($271.73M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($237.20M) | Nov 7, 2019 |
| FY2018 | Dec 30, 2017 | ($240.26M) | Nov 7, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $36.40M | Apr 13, 2026 |
| FY2024 | Dec 28, 2024 | $14.16M | Apr 17, 2025 |
| FY2024 | Dec 30, 2023 | $5.71M | Apr 17, 2025 |
| FY2023 | Dec 31, 2022 | $8.26M | Mar 14, 2024 |
| FY2022 | Dec 25, 2021 | $26.79M | Mar 14, 2023 |
| FY2021 | Dec 26, 2020 | $17.11M | Mar 14, 2022 |
| FY2020 | Dec 28, 2019 | $6.03M | Mar 5, 2021 |
| FY2019 | Dec 29, 2018 | $14.33M | Mar 11, 2020 |
| FY2019 | Dec 30, 2017 | $24.85M | Mar 11, 2020 |
| FY2019 | Dec 31, 2016 | $15.82M | Mar 11, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | 0 | Apr 13, 2026 |
| FY2025 | Dec 28, 2024 | 0 | Apr 13, 2026 |
| FY2024 | Dec 30, 2023 | 0 | Apr 17, 2025 |
| FY2024 | Dec 31, 2022 | 0 | Apr 17, 2025 |
| FY2023 | Dec 25, 2021 | 0 | Mar 14, 2024 |
| FY2020 | Dec 26, 2020 | 0 | Mar 5, 2021 |
| FY2020 | Sep 26, 2020 | 0 | Mar 5, 2021 |
| FY2020 | Jun 27, 2020 | 0 | Mar 5, 2021 |
| FY2020 | Mar 28, 2020 | 0 | Mar 5, 2021 |
| FY2016 | Dec 31, 2016 | 0 | Mar 23, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | 0 | Apr 13, 2026 |
| FY2025 | Dec 28, 2024 | 0 | Apr 13, 2026 |
| FY2024 | Dec 30, 2023 | 0 | Apr 17, 2025 |
| FY2024 | Dec 31, 2022 | 0 | Apr 17, 2025 |
| FY2023 | Dec 25, 2021 | 0 | Mar 14, 2024 |
| FY2020 | Dec 26, 2020 | 0 | Mar 5, 2021 |
| FY2020 | Sep 26, 2020 | 0 | Mar 5, 2021 |
| FY2020 | Jun 27, 2020 | 0 | Mar 5, 2021 |
| FY2020 | Mar 28, 2020 | 0 | Mar 5, 2021 |
| FY2016 | Dec 31, 2016 | 0 | Mar 23, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | 176.90M | Apr 13, 2026 |
| FY2025 | Dec 28, 2024 | 156.12M | Apr 13, 2026 |
| FY2024 | Dec 30, 2023 | 112.25M | Apr 17, 2025 |
| FY2023 | Dec 31, 2022 | 92.88M | Mar 14, 2024 |
| FY2022 | Dec 25, 2021 | 89.99M | Mar 14, 2023 |
| FY2021 | Dec 26, 2020 | 85.44M | Mar 14, 2022 |
| FY2020 | Dec 28, 2019 | 82.54M | Mar 5, 2021 |
| FY2019 | Dec 29, 2018 | 74.01M | Mar 11, 2020 |
| FY2018 | Dec 30, 2017 | 73.06M | Nov 7, 2019 |
| FY2017 | Dec 31, 2016 | 64.54M | Mar 23, 2018 |